Asuragen to Provide GLP Laboratory Testing Services to a Biotechnology Organization
News May 30, 2007
Asuragen, a cGMP/GLP facility, is dedicated to helping the scientific community and industry to discover and develop new products for the advancement of cancer research and companion diagnostics.
“We are committed to applying our RNA expertise to produce the data quality required in clinical studies with organizations such as Millennium and believe that research like this may enable companion diagnostics and support the value of personalized medicine,” commented Scott Hunicke-Smith, V.P. and General Manager of Asuragen Services.
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE
Is there a link between differences in IQ test performance and the activity of certain genes? Researchers have shown that modifications in the structure of a specific gene have a negative impact on individual test performance. This suggests that environmentally-induced epigenetic changes to our genetic material have a greater impact on intelligence than previously thought.